The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients

In this study, we investigated the effect of pre-treatment with demethylating agent decitabine on susceptibility to chemotherapeutic drugs in HL60/ADR, Kasumi-1 and primary AML cells. Cytotoxic effect was increased by decitabine through activation of p53 and inhibition of c-Myc, Survivin and Bcl-2....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Jiang, Xuejie, Wang, Zhixiang, Ding, Bingjie, Yin, Changxin, Zhong, Qingxiu, Carter, Bing Z., Yu, Guopan, Jiang, Ling, Ye, Jieyu, Dai, Min, Zhang, Yu, Liang, Shuang, Zhao, Qingxia, Liu, Qifa, Meng, Fanyi
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741789/
https://ncbi.nlm.nih.gov/pubmed/26384351
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados